Molecular analysis of hormone receptor positive (luminal) breast cancers - What have we learnt?

European Journal of Cancer

Volumn 44, Issue 18, 2008, Pages 2813-2818

  Loi, Sherene ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Gene expression profiling; Luminal subtypes; Tamoxifen resistance

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; GENE EXPRESSION; HUMAN; MICROARRAY ANALYSIS; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; PROGNOSIS; RECEPTORS, ESTROGEN; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 56949088317     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.09.012     Document Type: Article

References (32)

1. Daidone M.G., Coradini D., Martelli G., and Veneroni S. Primary breast cancer in elderly women: biological profile and relation with clinical outcome. Crit Rev Oncol Hematol 45 3 (2003) 313-325
2. EBCTG. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687-717.
3. Perou C.M., Sorlie T., Elsen M.B., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
4. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98 19 (2001) 10869-10874
5. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100 14 (2003) 8418-8423
6. Sotiriou C., Neo S.Y., McShane L.M., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100 18 (2003) 10393-10398
7. Hu Z., Fan C., Oh D.S., et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genom 7 (2006) 96
8. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New Engl J Med 351 27 (2004) 2817-2826
9. Sparano J.A., and Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26 5 (2008) 721-728
10. Oh D.S., Troester M.A., Usary J., et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 24 11 (2006) 1656-1664
11. Sotiriou C., Wirapati P., Loi S., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98 4 (2006) 262-272
12. Loi S., Haibe-Kains B., Desmedt C., et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25 10 (2007) 1239-1246
13. Mootha V.K., Lindgren C.M., Eriksson K.F., et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34 3 (2003) 267-273
14. Subramanian A., Tamayo P., Mootha V.K., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci 102 43 (2005) 15545-15550
15. Loi S, Sotiriou C, Haibe-Kains B, et al. Investigating tamoxifen resistance in the luminal B estrogen receptor positive breast cancer subtype: tailoring treatment in hormone responsive breast cancer. J Clin Oncol ASCO Ann Meeting Proc 2007;25(18S (June 20 Supplement))10603.
16. Loi S, Haibe-Kains B, Phillips WA, et al. Identification of potential therapeutic targets in estrogen receptor-positive breast cancer by gene expression profiling. In: 2007 ASCO breast cancer symposium, abstract 26, San Francisco, CA, 2007.
17. Ma X.J., Wang Z., Ryan P.D., et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5 6 (2004) 607-616
18. Goetz M.P., Suman V.J., Ingle J.N., et al. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res 12 7 Pt 1 (2006) 2080-2087
19. Ma X.J., Hilsenbeck S.G., Wang W., et al. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol 24 28 (2006) 4611-4619
20. Jerevall P.L., Brommesson S., Strand C., et al. Exploring the two-gene ratio in breast cancer-independent roles for HOXB13 and IL17BR in prediction of clinical outcome. Breast Cancer Res Treat (2007)
21. Jansen M.P., Sieuwerts A.M., Look M.P., et al. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study. J Clin Oncol 25 6 (2007) 662-668
22. Reid J.F., Lusa L., De Cecco L., et al. Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst 97 12 (2005) 927-930
23. Wang Z., Dahiya S., Provencher H., et al. The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer. Clin Cancer Res 13 21 (2007) 6327-6334
24. Fan C., Oh D.S., Wessels L., et al. Concordance among gene-expression-based predictors for breast cancer. New Engl J Med 355 6 (2006) 560-569
25. Kok M., Linn S.C., Van Laar R.K., et al. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat (2008)
26. Lin N.U., and Winer E.P. Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol 26 5 (2008) 798-805
27. Goss P.E., Ingle J.N., Martino S., et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol 25 15 (2007) 2006-2011
28. Dowsett M., Allred C., Knox J., et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol 26 7 (2008) 1059-1065
29. Viale G., Regan M.M., and Maiorano E. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal women with early breast cancer: results from the BIG1-98 Collaborative Groups. J Clin Oncol 25 (2007) 3846-3852
30. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24 23 (2006) 3726-3734
31. Rouzier R., Perou C.M., Symmans W.F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11 16 (2005) 5678-5685
32. Wolmark N., Wang J., Mamounas E., Bryant J., and Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30 (2001) 96-102